Table 1.
Monoclonal antibody products in the US, Europe, and global markets approved for diseases.
| Brand name | Company reporting US sales | Company reporting EU sales | Year of approval | Treatment |
|---|---|---|---|---|
| AlprolIX (Factor IX Fc fusion protein) | Biogen Idec | Sobi and Biogen Idec | 2014 | Hemophilia B |
| Cyramza (ramucirumab) | Eli Lilly and Co. | Eli Lilly and Co. | 2014 | Gastric cancer and non-small cell lung cancer |
| Eloctate (Factor VIII Fc fusion protein) | Biogen Idec | Sobi and Biogen Idec | 2014 | Anti-hemophilic Factor |
| Entyvio (vedolizumab) | Takeda Pharmaceutical Co. | Takeda Pharmaceutical Co. | 2014 | Ulcerative colitis (UC)/Crohn's disease (CD) |
| Keytruda (pembrolizumab) | Merck & Co. | Merck & Co. | 2014 | Melanoma |
| Sylvant (siltuximab) | Johnson & Johnson | Johnson & Johnson | 2014 | Multicentric Castleman's Disease (MCD) |
| Inflectra (infliximab [biosimilar]) | N/A | Hospira | 2013 | Tumor necrosis |
| Kadcyla (ado-trastuzumab emtansine) | Roche | Roche | 2013 | Metastatic breast cancer |
| Lemtrada (alemtuzumab) | N/A | Sanofi | 2013 | Relapsing form of multiple sclerosis (MS) |
| Gazyva (obinutuzumab) | Roche | Roche | 2013 | Chronic lymphocytic leukemia (CLL) |
| Remsima (infliximab [biosimilar]) | N/A | Celltrion | 2013 | Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and plaque psoriasis |
| Perjeta (pertuzumab) | Roche | Roche | 2012 | Human epidermal growth factor receptor 2 (HER2)/neu-positive) metastatic breast cancer |
| Abthrax (raxibacumab) | GlaxoSmithKline | GlaxoSmithKline | 2012 | Inhalational anthrax |
| Prolia (denosumab) | Amgen | GlaxoSmithKline | 2011 | Osteoporosis |
| Adcetris (brentuximab vedotin) | Seattle Genetics | Takeda Pharmaceutical Co. | 2011 | Hodgkin lymphoma |
| Benlysta (belimumab) | GlaxoSmithKline | GlaxoSmithKline | 2011 | Systemic lupus erythematosus (SLE/lupus) |
| Eylea (aflibercept) | Regeneron Pharmaceuticals | Bayer Healthcare Pharmaceuticals | 2011 | Macular degeneration |
| Nulojix (belatacept) | Bristol-Myers Squibb | Bristol-Myers Squibb | 2011 | Prevention of transplant rejection |
| Xgeva (denosumab) | Amgen | Amgen | 2010 | Prevention of bone fractures and other skeletal bone tumor conditions |
| Arzerra (ofatumumab) | GlaxoSmithKline | GlaxoSmithKline | 2009 | Chronic lymphocytic leukemia (CLL) |
| Ilaris (canakinumab) | Novartis Pharmaceuticals | Novartis Pharmaceuticals | 2009 | Systemic Juvenile Idiopathic Arthritis (SJIA) |
| Actemra (tocilizumab) | Roche | Roche | 2009 | Moderate to severe rheumatoid arthritis |
| Simponi Aria (golimumab) | Johnson & Johnson | Merck & Co. | 2009 | Rheumatoid arthritis |
| Stelara (ustekinumab) | Johnson & Johnson | Johnson & Johnson | 2009 | Plaque psoriasis, psoriatic arthritis and Crohn's disease |
| Removab (catumaxomab) | N/A | NeoPharm Group | 2009 | Malignant ascites |
| Arcalyst (rilonacept) | Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | 2008 | Familial Cold Auto-inflammatory Syndrome/Muckle-Wells Syndrome |
| Cimzia (certolizumab pegol) | UCB | UCB | 2008 | Rheumatoid Arthritis |
| Nplate (romiplostim) | Amgen | Amgen | 2008 | Low blood platelet counts |
| Soliris (eculizumab) | Alexion Pharmaceuticals | Alexion Pharmaceuticals | 2007 | Paroxysmal nocturnal hemoglobinuria (PNH), and Atypical hemolytic uremic syndrome (aHUS) |
| Lucentis (ranibizumab) | Roche | Novartis Pharmaceuticals | 2006 | Macular degeneration |
| Vectibix (panitumumab) | Amgen | Amgen | 2006 | Metastatic colorectal cancer |
| Orencia (abatacept) | Bristol-Myers Squibb | Bristol-Myers Squibb | 2005 | Rheumatoid arthritis |
| Avastin (bevacizumab) | Roche | Roche | 2004 | Various cancers and eye disease |
| Tysabri (natalizumab) | Biogen Idec | Biogen Idec | 2004 | MS and Crohn's disease |
| Erbitux (cetuximab) | Bristol-Myers Squibb | Merck KGaA | 2004 | Metastatic colorectal cancer, metastatic non-small cell lung cancer, head and neck cancer |
| Humira (adalimumab) | AbbVie | AbbVie | 2002 | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa |
| Enbrel (etanercept) | Amgen | Pfizer | 1998 | Rheumatoid arthritis |
| Herceptin (trastuzumab) | Roche | Roche | 1998 | Breast cancer/stomach cancer |
| Remicade (infliximab) | Johnson & Johnson | Merck & Co. | 1998 | Crohn's Disease |
| Simulect (basiliximab) | Novartis Pharmaceuticals | Novartis Pharmaceuticals | 1998 | Prevention of organ rejection |
| Synagis (palivizumab) | AstraZeneca | Abbvie | 1998 | Lung disease caused by respiratory syncytial virus (RSV) |
| Rituxan (rituximab) | Roche | Roche | 1997 | Non-Hodgkin's lymphoma or chronic lymphocytic leukemia |
| ReoPro (abciximab) | Lilly | Lilly | 1994 | Prevention of blood clots |